



## Press release

### TxCell: financial information for the 3<sup>rd</sup> quarter of 2017

Valbonne, France, October 19, 2017, 5.45pm CEST – TxCell SA (FR0010127662 – TXCL), a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, today reports its revenues for the third quarter of 2017 and its cash position as of September 30, 2017.

#### Cash position and revenues as of September 30, 2017

As of September 30, 2017, TxCell's cash and cash equivalents amounted to €7.0 million<sup>1</sup>, including €1.0 million for the partial pre-funding of TxCell's 2017 research tax credit.

The proceeds from the potential exercise of all the warrants which were attached to new shares issued as part of the February 2017 capital increase would enable TxCell to finance its activities through to the IND approval to initiate a first-in-man study with a CAR-Treg candidate. This is expected by the end of 2018. TxCell is also looking at alternative financing options should these warrants not be fully exercised at maturity. The Company expects to communicate shortly regarding these options.

As expected, TxCell did not generate revenues during the third quarter of 2017. TxCell confirms its operating cash burn guidance for the full year 2017 of up to €13 million.

#### Recent progress with TxCell's CAR-Treg platform

In September 2017, TxCell and its academic partner, UBC, presented new preclinical proof-of-concept data as part of their CAR-Treg program targeting the prevention of chronic rejection after organ transplantation<sup>2</sup>. Additional Treg and CAR-Treg related data were also presented in several international conferences in September and October 2017<sup>3,4,5,6</sup>.

Ongoing *in vitro* and *in vivo* studies conducted by TxCell are showing promising preliminary results in relevant models of autoimmune diseases, including multiple sclerosis, confirming TxCell's CAR-Treg platform strategy. In the next few months, TxCell will present new proof-of-

---

<sup>1</sup> Unaudited data.

<sup>2</sup> Levings MK, Alloantigen-specific regulatory T-cells generated with a chimeric antigen receptor. Oral presentation, 18<sup>th</sup> Congress of the European Society for Organ Transplantation (ESOT), September 24-27, 2017, Barcelona, Spain.

<sup>3</sup> Zhou L (presenting author), Abel T, Schneider IC, Beghelli S, Labbal F, David M, Menkova-Garnier I and Meyer F. Designing the next generation of chimeric Antigen receptors for Regulatory T cell therapy through in silico modeling-guided single chain Fv engineering. Oral presentation & poster N°12, CAR-TCR Summit 2017, September 5-8, 2017.

<sup>4</sup> Ménoiret S, Guillonnet C, Anegon I (presenting author), CD8+ Treg new players in allograft tolerance. Oral presentation, Final Conference of the European COST Consortium 'Action to Focus & Accelerate Cell-based Tolerogenic Therapies' (A FACTT), October 9-11, 2017, Barcelona, Spain.

<sup>5</sup> Fenard D (presenting author), David M, Abel T, Marchetti I, Asnagli H, Zhou L and Meyer F, Combination of transduction enhancers with Ecotropic-MLV pseudotyped lentiviral vectors enables highly efficient transfer of chimeric antigen receptors into murine T effector and T regulatory lymphocytes. Poster presentation, 25<sup>th</sup> Anniversary Congress of the European Society of Gene & Cell Therapy (ESGCT), October 17-20, 2017, Berlin, Germany.

<sup>6</sup> Abel T (presenting author), Schneider IC, Beghelli S, Labbal F, David M, Zhou M and Meyer F, Designing the next generation of chimeric Antigen receptors for Regulatory T cell therapy through in silico modeling-guided single chain Fv engineering. Poster presentation, 25<sup>th</sup> Anniversary Congress of the European Society of Gene & Cell Therapy (ESGCT), October 17-20, 2017, Berlin, Germany.

concept data in clinically relevant mouse models with several candidates at appropriate scientific conferences and/or in peer-reviewed journals.

## About TxCell – [www.txcell.com](http://www.txcell.com)

TxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases with high unmet medical need. TxCell is targeting transplant rejection as well as a range of autoimmune diseases (both T-cell and B-cell-mediated), including multiple sclerosis, lupus nephritis and bullous pemphigoid.

TxCell's cellular immunotherapies are based on regulatory T lymphocytes (Tregs). Tregs are a T cell population discovered in the nineties for which anti-inflammatory properties have been demonstrated. Contrary to conventional approaches based on non-specific polyclonal Tregs, TxCell is exclusively developing engineered antigen-specific Tregs, where the antigen specificity is brought by a Chimeric Antigen Receptor (CAR) (CAR-Treg cells).

Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 46 employees.

## Upcoming events

### Scientific and medical conferences

Oct 17-20 ESGCT 2017 (European Society of Gene & Cell Therapy) Berlin (DE)

### Financial and business conferences

Nov 6-9	BIO-Europe	Berlin (DE)
Nov 9	5 <sup>th</sup> Annual European Advanced Therapies Investor Day	London (UK)
Nov 14	Inv€\$tival Showcase	London (UK)
Nov 15-16	Jefferies 2017 Global Healthcare Conference	London (UK)
Nov 23-24	Actionaria	Paris (FR)
Dec 19	Invest Securities BioMed Event	Paris (FR)

## Contacts

### TxCell

Caroline Courme  
IR & Communication Director  
Tel: +33(0) 4 97 21 83 00  
[caroline.courme@txcell.com](mailto:caroline.courme@txcell.com)

### Image Box – Press relations

Neil Hunter / Michelle Boxall  
Tel: +44(0) 20 8943 4685  
[neil.hunter@imageboxpr.co.uk](mailto:neil.hunter@imageboxpr.co.uk)  
[michelle.boxall@imageboxpr.co.uk](mailto:michelle.boxall@imageboxpr.co.uk)

### NewCap – Investor relations

Julien Perez / Mathilde Bohin  
Tel: +33 (0)1 44 71 98 52  
[txcell@newcap.eu](mailto:txcell@newcap.eu)

## Forward-Looking Statements – TxCell

This press release contains certain forward-looking statements relating to the business of TxCell, which shall not be considered *per se* as historical facts, including TxCell's ability to develop, market, commercialize and achieve market acceptance for specific products, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements, needs for additional financing. In addition, even if the actual results or development of TxCell are consistent with the forward-looking statements contained in this press release, those results or developments of TxCell may not be indicative of their in the future.

In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. Although the management of TxCell believes that these forward-looking statements are reasonably made, they are based largely on the current expectations of TxCell as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results,

performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of TxCell could be affected by, among other things, uncertainties involved in the development of the Company's products, which may not succeed, or in the delivery of TxCell's products marketing authorizations by the relevant regulatory authorities and, in general, any factor that could affect TxCell capacity to commercialize the products it develops, as well as, any other risk and uncertainties developed or identified in any public documents filed by TxCell with the AMF, included those listed in chapter 4 "Risk factors" of the 2016 *document de référence* (registration document) approved by the AMF on April 26, 2017 under number R.17-024. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Notwithstanding the compliance with article 223-1 of the General Regulation of the AMF (the information disclosed must be "accurate, precise and fairly presented"), TxCell is providing the information in these materials as of this press release, and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.